Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-21

AUTHORS

Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, Yong Yuan

ABSTRACT

BackgroundAs treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3.MethodsUtilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12 weeks of treatment with daclatasvir + sofosbuvir (DCV + SOF) was compared to 24 weeks of treatment with sofosbuvir + ribavirin (SOF + RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens.ResultsIn the base case analysis, DCV + SOF was found to be dominant over SOF + RBV in treatment-naïve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV + SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of £8817.ConclusionsWhen compared to 24 weeks of SOF + RBV, 12 weeks of treatment with DCV + SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection. More... »

PAGES

15

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4

DOI

http://dx.doi.org/10.1186/s12962-017-0077-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090851960

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28736505


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "School of Human & Health Sciences, Swansea University, Swansea, UK", 
          "id": "http://www.grid.ac/institutes/grid.4827.9", 
          "name": [
            "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
            "School of Human & Health Sciences, Swansea University, Swansea, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "Phil", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/grid.512413.0", 
          "name": [
            "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Webster", 
        "givenName": "Samantha", 
        "id": "sg:person.01165715264.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165715264.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK", 
          "id": "http://www.grid.ac/institutes/grid.512413.0", 
          "name": [
            "Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ward", 
        "givenName": "Thomas", 
        "id": "sg:person.01003353464.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003353464.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UK HEOR, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "UK HEOR, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brenner", 
        "givenName": "Michael", 
        "id": "sg:person.01234030464.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234030464.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalsekar", 
        "givenName": "Anupama", 
        "id": "sg:person.01247570417.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247570417.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA", 
          "id": "http://www.grid.ac/institutes/grid.419971.3", 
          "name": [
            "World Wide Health Economics and Outcomes Research, Bristol\u2013Myers Squibb Pharmaceuticals Ltd, Princeton, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Yong", 
        "id": "sg:person.01253410531.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253410531.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40258-012-0002-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008579116", 
          "https://doi.org/10.1007/s40258-012-0002-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-016-0865-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005166928", 
          "https://doi.org/10.1007/s10198-016-0865-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07-21", 
    "datePublishedReg": "2017-07-21", 
    "description": "BackgroundAs treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3.MethodsUtilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12\u00a0weeks of treatment with daclatasvir\u00a0+\u00a0sofosbuvir (DCV\u00a0+\u00a0SOF) was compared to 24\u00a0weeks of treatment with sofosbuvir\u00a0+\u00a0ribavirin (SOF\u00a0+\u00a0RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens.ResultsIn the base case analysis, DCV\u00a0+\u00a0SOF was found to be dominant over SOF\u00a0+\u00a0RBV in treatment-na\u00efve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV\u00a0+\u00a0SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of \u00a38817.ConclusionsWhen compared to 24\u00a0weeks of SOF\u00a0+\u00a0RBV, 12\u00a0weeks of treatment with DCV\u00a0+\u00a0SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12962-017-0077-4", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032048", 
        "issn": [
          "1478-7547"
        ], 
        "name": "Cost Effectiveness and Resource Allocation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "weeks of treatment", 
      "interferon-containing regimens", 
      "direct acting antivirals", 
      "treatment options", 
      "genotype 3 hepatitis C virus", 
      "hepatitis C virus genotype 3", 
      "genotype 3 HCV infection", 
      "matching-adjusted indirect comparison", 
      "chronic hepatitis C", 
      "interferon-free regimens", 
      "incremental cost-effectiveness ratio", 
      "weeks of SOF", 
      "treatment-na\u00efve patients", 
      "virus genotype 3", 
      "hepatitis C virus", 
      "faster disease progression", 
      "clinical trial data", 
      "cost-effectiveness ratio", 
      "base-case analysis", 
      "cost-utility analysis", 
      "HCV infection", 
      "hepatitis C", 
      "intolerant patients", 
      "HCV genotypes", 
      "C virus", 
      "genotype 3", 
      "disease progression", 
      "indirect comparison", 
      "patients", 
      "regimens", 
      "trial data", 
      "sofosbuvir", 
      "weeks", 
      "treatment", 
      "ribavirin", 
      "daclatasvir", 
      "lower rates", 
      "improved quality", 
      "RBV", 
      "SOF", 
      "DCV", 
      "options", 
      "antivirals", 
      "infection", 
      "ResultsIn", 
      "appropriate allocation", 
      "progression", 
      "virus", 
      "total cost", 
      "genotypes", 
      "high cost", 
      "analysis", 
      "life", 
      "rate", 
      "UK", 
      "case analysis", 
      "data", 
      "quality", 
      "ratio", 
      "comparison", 
      "results", 
      "Markov model", 
      "cost", 
      "values", 
      "model", 
      "model inputs", 
      "input", 
      "resources", 
      "allocation", 
      "economic value"
    ], 
    "name": "Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus", 
    "pagination": "15", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090851960"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12962-017-0077-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28736505"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12962-017-0077-4", 
      "https://app.dimensions.ai/details/publication/pub.1090851960"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_734.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12962-017-0077-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12962-017-0077-4'


 

This table displays all metadata directly associated to this object as RDF triples.

183 TRIPLES      21 PREDICATES      97 URIs      87 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12962-017-0077-4 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N72787cd8b3494e0a80968752aac99dd2
4 schema:citation sg:pub.10.1007/s10198-016-0865-3
5 sg:pub.10.1007/s40258-012-0002-0
6 schema:datePublished 2017-07-21
7 schema:datePublishedReg 2017-07-21
8 schema:description BackgroundAs treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated with faster disease progression and has fewer treatment options, historically, than other HCV genotypes. This analysis aims to estimate the comparative cost-effectiveness of two recently licenced interferon-free regimens for the treatment of HCV genotype 3.MethodsUtilising a published Markov model and results of a matching-adjusted indirect comparison of recently published clinical trial data (ALLY-3 and VALENCE, respectively), 12 weeks of treatment with daclatasvir + sofosbuvir (DCV + SOF) was compared to 24 weeks of treatment with sofosbuvir + ribavirin (SOF + RBV). UK-specific model inputs were used to inform a cost-utility analysis of these regimens.ResultsIn the base case analysis, DCV + SOF was found to be dominant over SOF + RBV in treatment-naïve patients, patients that had previously been treated, and patients that are intolerant to, or ineligible for, interferon-containing regimens. Given the low rates of treatment currently observed in the UK, DCV + SOF was also compared to no treatment in the interferon-ineligible/intolerant patients, and may be considered cost-effective with an incremental cost-effectiveness ratio of £8817.ConclusionsWhen compared to 24 weeks of SOF + RBV, 12 weeks of treatment with DCV + SOF results in improved quality of life and reduced total costs, and therefore is likely to represent significant clinical and economic value as a treatment option for genotype 3 HCV infection.
9 schema:genre article
10 schema:isAccessibleForFree true
11 schema:isPartOf N106ad47dad7148e681c41a54ee282203
12 Nfd62e02484f74774b0a55ce11008bde0
13 sg:journal.1032048
14 schema:keywords C virus
15 DCV
16 HCV genotypes
17 HCV infection
18 Markov model
19 RBV
20 ResultsIn
21 SOF
22 UK
23 allocation
24 analysis
25 antivirals
26 appropriate allocation
27 base-case analysis
28 case analysis
29 chronic hepatitis C
30 clinical trial data
31 comparison
32 cost
33 cost-effectiveness ratio
34 cost-utility analysis
35 daclatasvir
36 data
37 direct acting antivirals
38 disease progression
39 economic value
40 faster disease progression
41 genotype 3
42 genotype 3 HCV infection
43 genotype 3 hepatitis C virus
44 genotypes
45 hepatitis C
46 hepatitis C virus
47 hepatitis C virus genotype 3
48 high cost
49 improved quality
50 incremental cost-effectiveness ratio
51 indirect comparison
52 infection
53 input
54 interferon-containing regimens
55 interferon-free regimens
56 intolerant patients
57 life
58 lower rates
59 matching-adjusted indirect comparison
60 model
61 model inputs
62 options
63 patients
64 progression
65 quality
66 rate
67 ratio
68 regimens
69 resources
70 results
71 ribavirin
72 sofosbuvir
73 total cost
74 treatment
75 treatment options
76 treatment-naïve patients
77 trial data
78 values
79 virus
80 virus genotype 3
81 weeks
82 weeks of SOF
83 weeks of treatment
84 schema:name Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
85 schema:pagination 15
86 schema:productId N730480ddbc55443981e391c84da594be
87 Nbe6a024d9cca41268d3967f0bf0c8a86
88 Nef630cb2f6eb438baca143e14a6e1f84
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090851960
90 https://doi.org/10.1186/s12962-017-0077-4
91 schema:sdDatePublished 2022-12-01T06:36
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher Necf0180076504c4e930e2abd8b1bfec5
94 schema:url https://doi.org/10.1186/s12962-017-0077-4
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N0a4c151aed834bc288411ac70e809333 rdf:first sg:person.01253410531.33
99 rdf:rest rdf:nil
100 N106ad47dad7148e681c41a54ee282203 schema:volumeNumber 15
101 rdf:type schema:PublicationVolume
102 N15d04be49ed74b45841bdba2012b2b1a rdf:first sg:person.01234030464.96
103 rdf:rest Nd919740f8760489a84103e2583c022a8
104 N640ef2a8ceac4b67a6bcc0c18e9588f9 rdf:first sg:person.01003353464.51
105 rdf:rest N15d04be49ed74b45841bdba2012b2b1a
106 N667f1a3a04984759ade4a34dc7ce2c41 rdf:first sg:person.01165715264.65
107 rdf:rest N640ef2a8ceac4b67a6bcc0c18e9588f9
108 N72787cd8b3494e0a80968752aac99dd2 rdf:first sg:person.01346767345.38
109 rdf:rest N667f1a3a04984759ade4a34dc7ce2c41
110 N730480ddbc55443981e391c84da594be schema:name pubmed_id
111 schema:value 28736505
112 rdf:type schema:PropertyValue
113 Nbe6a024d9cca41268d3967f0bf0c8a86 schema:name dimensions_id
114 schema:value pub.1090851960
115 rdf:type schema:PropertyValue
116 Nd919740f8760489a84103e2583c022a8 rdf:first sg:person.01247570417.25
117 rdf:rest N0a4c151aed834bc288411ac70e809333
118 Necf0180076504c4e930e2abd8b1bfec5 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Nef630cb2f6eb438baca143e14a6e1f84 schema:name doi
121 schema:value 10.1186/s12962-017-0077-4
122 rdf:type schema:PropertyValue
123 Nfd62e02484f74774b0a55ce11008bde0 schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
126 schema:name Economics
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
129 schema:name Applied Economics
130 rdf:type schema:DefinedTerm
131 sg:journal.1032048 schema:issn 1478-7547
132 schema:name Cost Effectiveness and Resource Allocation
133 schema:publisher Springer Nature
134 rdf:type schema:Periodical
135 sg:person.01003353464.51 schema:affiliation grid-institutes:grid.512413.0
136 schema:familyName Ward
137 schema:givenName Thomas
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003353464.51
139 rdf:type schema:Person
140 sg:person.01165715264.65 schema:affiliation grid-institutes:grid.512413.0
141 schema:familyName Webster
142 schema:givenName Samantha
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165715264.65
144 rdf:type schema:Person
145 sg:person.01234030464.96 schema:affiliation grid-institutes:None
146 schema:familyName Brenner
147 schema:givenName Michael
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234030464.96
149 rdf:type schema:Person
150 sg:person.01247570417.25 schema:affiliation grid-institutes:grid.419971.3
151 schema:familyName Kalsekar
152 schema:givenName Anupama
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247570417.25
154 rdf:type schema:Person
155 sg:person.01253410531.33 schema:affiliation grid-institutes:grid.419971.3
156 schema:familyName Yuan
157 schema:givenName Yong
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253410531.33
159 rdf:type schema:Person
160 sg:person.01346767345.38 schema:affiliation grid-institutes:grid.4827.9
161 schema:familyName McEwan
162 schema:givenName Phil
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
164 rdf:type schema:Person
165 sg:pub.10.1007/s10198-016-0865-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005166928
166 https://doi.org/10.1007/s10198-016-0865-3
167 rdf:type schema:CreativeWork
168 sg:pub.10.1007/s40258-012-0002-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008579116
169 https://doi.org/10.1007/s40258-012-0002-0
170 rdf:type schema:CreativeWork
171 grid-institutes:None schema:alternateName UK HEOR, Bristol–Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
172 schema:name UK HEOR, Bristol–Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
173 rdf:type schema:Organization
174 grid-institutes:grid.419971.3 schema:alternateName World Wide Health Economics and Outcomes Research, Bristol–Myers Squibb Pharmaceuticals Ltd, Princeton, USA
175 schema:name World Wide Health Economics and Outcomes Research, Bristol–Myers Squibb Pharmaceuticals Ltd, Princeton, USA
176 rdf:type schema:Organization
177 grid-institutes:grid.4827.9 schema:alternateName School of Human & Health Sciences, Swansea University, Swansea, UK
178 schema:name Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
179 School of Human & Health Sciences, Swansea University, Swansea, UK
180 rdf:type schema:Organization
181 grid-institutes:grid.512413.0 schema:alternateName Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
182 schema:name Health Economics & Outcomes Research Ltd, 9 Oak Tree Court, Mulberry Drive, Cardiff Gate Business Park, CF23 8RS, Cardiff, UK
183 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...